Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALERZIN: Levocetirizine/Pseudoephedrine FDC vs Levocetirizine in Allergic Rhinitis
NCT05637710Phase 3Withdrawn
- Sponsor
- Eurofarma
- Start
- Mar 2026
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of levocetirizine and pseudoephedrine in allergic rhinitis (AR) (2 arms), sponsored by Eurofarma. Primary endpoint: Severity of nasal allergy symptoms in the last 24 hours at 7 days. Planned start Mar 2026; status: withdrawn.
02
Drugs
levocetirizinepseudoephedrine
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT05637710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05637710.